Today: 30 April 2026
Browse Category

NASDAQ:BTCM 11 October 2025 - 8 February 2026

Bitmine Immersion Technologies stock jumps 18% into weekend as crypto steadies — what to watch Monday

Bitmine Immersion Technologies stock jumps 18% into weekend as crypto steadies — what to watch Monday

Bitmine Immersion Technologies shares jumped 17.6% to $20.47 Friday, rebounding after four days of losses. Bitcoin and ether both surged over 10%, but demand for downside protection in crypto options remained high. Bitmine’s stock tracked crypto moves closely, reflecting its large ether and bitcoin holdings. About 74 million Bitmine shares traded in a session that saw the stock swing between $18.70 and $20.70.
8 February 2026
···
Ethereum’s Uptober Rollercoaster: Near-Record Highs, Flash Crash, and the $5K Question

Ethereum’s Uptober Rollercoaster: Near-Record Highs, Flash Crash, and the $5K Question

Ethereum plunged nearly 16% on Oct. 10, briefly dropping below $3,700 after former President Trump announced a 100% tariff on Chinese goods, triggering a crypto market sell-off. Over $600 million in crypto futures were liquidated that day, including $235 million in ETH longs. Despite the volatility, spot Ethereum ETFs saw $1.5 billion in net inflows in early October. BitMine Immersion disclosed it holds 2.83 million ETH.
11 October 2025
···

Stock Market Today

  • Why This ASX 200 Biotech Stock Is Under Pressure
    April 30, 2026, 3:23 PM EDT. The ASX 200 biotech sector is facing pressure amid recent market developments. Key factors include regulatory challenges and clinical trial setbacks affecting investor sentiment. This volatility impacts stock valuations and trading volumes, highlighting risks within the biotech industry. Investors are advised to monitor updates carefully and consult financial professionals before making decisions. Recent movements underscore the sector's sensitivity to news flow and operational progress.

Latest article

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

30 April 2026
Option Care Health shares fell 28% to $19.44 after the company cut its 2026 revenue forecast and reported first-quarter sales of $1.35 billion, missing estimates. The company now expects 2026 revenue of $5.675–$5.775 billion, down from a prior range of $5.8–$6.0 billion, citing pressure in its chronic inflammatory disease portfolio. Adjusted profit guidance was unchanged.
Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

30 April 2026
Stellantis reported a first-quarter net profit of €377 million, reversing a €387 million loss a year earlier, aided by a €400 million expected U.S. tariff refund. Industrial free cash flow remained negative at €1.92 billion. Shares fell 6.4% to €6.22 after the results. CEO Antonio Filosa faces pressure ahead of a May 21 investor day to present a stronger turnaround plan.
Go toTop